baricitinib
Selected indexed studies
- Two Phase 3 Trials of Baricitinib for Alopecia Areata. (N Engl J Med, 2022) [PMID:35334197]
- Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. (N Engl J Med, 2017) [PMID:28199814]
- Baricitinib for the Treatment of Alopecia Areata. (Drugs, 2023) [PMID:37195491]
_Worker-drafted node — pending editorial review._
Connections
baricitinib is a side effect of
Sources
- Baricitinib for the Treatment of Alopecia Areata. (2023) pubmed
- Two Phase 3 Trials of Baricitinib for Alopecia Areata. (2022) pubmed
- Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. (2017) pubmed
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2). (2023) pubmed
- Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes. (2023) pubmed
- Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata. (2025) pubmed
- Baricitinib: A Review in Severe Alopecia Areata. (2023) pubmed
- Baricitinib: From Rheumatoid Arthritis to COVID-19. (2021) pubmed
- Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical Trial. (2024) pubmed
- Baricitinib for the treatment of atopic dermatitis. (2022) pubmed